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essential components of signal transduction pathways that regulate cancer cell proliferation, apoptosis
and angiogenesis, and therefore become potential targets for anticancer therapy. Most of TK inhibitors
(TKIs) are small molecular and hydrophobic compounds, thus they can rapidly reach their speciﬁc
intracellular targets and inhibit the activation of the related TKs. Unfortunately, accompanied with
patients who gain great beneﬁt of TKIs therapy, increasing evidences of acquired resistance to these
agents have been documented. The unveiling point mutations within the kinase domain, gene
ampliﬁcation or overexpression, or modiﬁcation of signaling pathway have been implicated in drug
resistance. Additionally, overexpression of ABC transporters is likely to set stage for resistant
development. In this review, we focus on the discussion of the molecular mechanisms of acquired
resistance to TKIs therapy. The mechanistic understanding may help to put forward new hypotheses on
drug development and design better therapies to overcome TKIs resistance.
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Carcinogenesis in numerous cases is based on a pathological
intracellular signal transduction, in which the activation of
speciﬁc tyrosine kinases plays a major role including regulation
of cell growth, differentiation, adhesion, motility, death and
so on1,2. Mutations in TKs and aberrant activation of their
intracellular signaling pathways have been causally linked to
cancers. So the connection has driven the development of a new
generation of drugs that block or attenuate TKs activity,
providing a broader therapeutic window with less toxicity and
high efﬁciency. Nowadays, targeted therapies represent an
integrative approach to cancer therapy that has already led to
important clinical results. Although several TKIs have been
approved by Food and Drug Administration (FDA) and
applied in the clinic or in the clinical trial, increasing evidences
have shown that cancer cells treated with TKIs tend to acquire
genetic modiﬁcations to escape the inhibition from these agents.
Insight into the molecular events underlying TKI-resistance is
needed for the development of new treatment approaches,
such as next generation TKIs, despite the mechanisms are
varied and some of them are uncertain. In this review, we
summarize the molecular mechanisms of acquired resistance to
TKIs therapy.2. Tyrosine kinases
The human protein kinase genome (also known as the kinome)
contains 518 protein kinase genes, including genes that encode
transmembrane receptor tyrosine kinases (RTKs) and soluble
cytoplasmic tyrosine kinases (also known as non-receptor tyrosine
kinases, NRTKs)3,4. Humans have 58 known RTKs which fall
into 20 subfamilies, including the well-known insulin receptor,
Fms-like tyrosine kinase 3 (FLT3), epidermal growth factor
receptor (EGFR), platelet-derived growth factor receptor
(PDGFR)3,5. All RTKs have a similar molecular architecture,
with ligand-binding domains in the extracellular region, a single
transmembrane helix, and a cytoplasmic region that contains the
protein tyrosine kinase (TK) domain plus additional carboxy (C-)
terminal and juxtamembrane regulatory regions6. Activation of
RTKs is initiated by hormones or binding of growth factors to
speciﬁc sites within the extracellular domain of the receptor. Upon
ligand binding, RTKs undergo a dimerization process (or a
conformational change), i.e., a bivalent ligand interacts simulta-
neously with two receptor molecules and effectively crosslinks
them into a dimeric complex3,6, resulting in autophosphorylation
of the tyrosine kinase domains3,7. Most tyrosine autophosphor-
ylation sites are located in non-catalytic regions of the receptor
molecule and function as binding sites for Src homology 2 (SH2)
or phosphotyrosine binding (PTB) domains of a variety of
signaling proteins7. Then the phosphotyrosine residues in the
cytoplasmic regions of RTKs are recognized as docking sites by
signaling factors such as PLCg1 through their SH2 domains and
hence link PTK activation to downstream signaling pathways8.
On the other hand, NRTKs account for third of the
approximately 90 known TKs which fall into 10 subfamilies
based on kinase domain sequence, including the well-char-
acterized Src, c-Abl, JAK. They are lack of transmembrane
domains and are found in the cytosol, the nucleus, and the
inner surface of the plasma membrane9. Normally, NRTKs
maintained in an inactive state through multiple mechanisms,including binding of inhibitory proteins or lipids or intramo-
lecular autoinhibition10. Activation of NRKTs occurs through
binding to transmembrane receptors or a variety of intracel-
lular signals including dissociation of inhibitors or transpho-
sphorylation by other tyrosine kinases. Upon tyrosine
phosphorylaton activation, immunoreceptor tyrosine-based
activation motifs (ITAMs) serve as a docking site for down-
stream signaling molecules and adapter proteins containing
SH2 or phosphotyrosine binding domains, leading to multiple
cascades of signal transmission11. The involvement of NRTKs
in cancer can occur through various mechanisms such as
overexpression, mutation, and translocation; and therefore,
many compounds have been developed attempting to inhibit
their activity12.
Taken together, the TKs’ functions are as a point of
convergence for diverse signaling pathways and deﬁne key
biological outcomes, such as cell proliferation, differentiation,
motility and survival, in response to a wide range of physio-
logical stimuli8. Phosphorylation of tyrosine residues in target
TKs is essential for maintaining cellular homeostasis and
modulating gene expression in various intercellular and intra-
cellular signaling pathways. TKs are therefore important
targets for basic research and drug development3,5.3. Small molecule tyrosine kinase inhibitors
Alterations of TKs signal transduction found in proliferative
disorders lead to the hypothesis that tyrosine kinase inhibitors
(TKIs) could have anticancer effects and, as a result, the
development of TKIs has become a hot area of anticancer
drug research.
The idea behind much of anti-TK drugs discovery is to ﬁnd
small molecules that directly inhibit the catalytic activity of the
kinase by interfering with the binding of ATP or substrates9.
Generally, most of these TKIs can be categorized into four
groups: (1) ATP-competitive inhibitors, which bind predomi-
nantly to the ATP-binding site of the kinase when this site is in
the active conformation; (2) inhibitors that recognize and bind
to the non-active conformation of the ATP-binding site of the
kinase, thus making activation energetically unfavorable;
(3) allosteric inhibitors, that bind outside of the ATP-binding
site, modifying the tridimensional structure of the receptor and
disrupting the interaction between the ATP and the kinase
pocket; and (4) covalent inhibitors, that bind irreversibly by
covalently bonding to the ATP-binding site of the target
kinase12. Some TKIs target a wide range of kinase, such as
Imatinib, which is a drug used to treat certain types of cancer.
By 2011, Imatinib has been approved by FDA to treat ten
different cancers, including all stages of CML, GISTs and Phþ
B-ALL. It is unclear whether this lack of selectivity should be
considered an advantage or a shortcoming versus non-selective
TKIs. However, many receptor tyrosine kinase pathways
(for example, PDGF, EGF and VEGF) are simultaneously
activated, suggesting that multi-target TKIs could be superior
to selective inhibitors of a single receptor3.
Until 2011, 11 tyrosine kinase inhibitors have received US
Food and Drug Administration approval as cancer treat-
ments. There are considerable efforts to develop small mole-
cule inhibitors for a host of other kinases that are implicated
in cancer and other diseases. Here we have summarized the
information of the TKIs in Table 113.
Table 1 Tyrosine kinase inhibitor approved by FDA until 2011.
Name Alternative
name
Targets Clinical application Chemical structure
Receptor tyrosine kinase inhibitors
Erlotinib Tarceva, OSI-
774
EGFR Advanced or metastatic NSCLC,
pancreatic cancer
Geﬁtinib Iressa,
ZD1839
EGFR Advanced or metastatic NSCLC
Lapatinib Tykerb, GW
572016
EGFR, HER2 HER-2þ advanced or metastatic
breast cancer
Pazopanib Votrient,
GW-786034
VEGFRs, PDGFRs, c-Kit Advanced RCC
Sorafenib Nexavar,
BAY43-9006
Raf kinase, VEGFR2, c-
Kit,
FLT3, PDGFR-b
Advanced RCC, advanced HCC
Sunitinib Sutent
SU11248
VEGFR, PDGFR,
c-Kit, FLT3, CSF-1R
Imatinib–resistant or intolerant GISTs,
metastatic RCC
Vandetanib Caprelsa
ZD6474
VEGFR, EGFR Metastatic medullary thyroid cancer
Non-receptor tyrosine kinase inhibitors
Crizotinib Xalkori ALK Advanced or metastatic ALKþ NSCLC
Dasatinib Sprycel, BMS
354825
BCR–ABL, SRC family,
c-Kit, EPHA2, PDGFR
All phases of CML with resistance to
prior therapy including imatinib,
PhþALL with resistance to prior
therapy
Imatinib Gleevec,
STI571
BCR–ABL, c-Kit, PDGFR All stages of CML, GISTs, Phþ
B-ALL, dermatoﬁbrosarcoma
Nilotinib Tasigna,
AMN107
BCR–ABL, PDGFR, c-Kit Chronic phase and accelerated phase
Phþ CML in adult patients resistant
to prior therapy, GISTs
Adapted from Wang et al.13.
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Yi-fan Chen, Li-wu Fu200Although chemists continue to develop novel cytotoxic agents
with unique mechanisms of action, many of these compounds
are still limited by their general toxicity to proliferating cells,
including some normal cells14. Targeted therapy provides a new
approach for cancer therapy that has the potential for avoiding
some of the drawbacks associated with cytotoxic chemother-
apy15. While most novel, target directed cancer drugs have
pregenomic origins, one can anticipate a post genomic wave of
sophisticated ‘‘smart drugs’’ to fundamentally change the treat-
ment of all cancers16. However, clinical and in vitro evidences
have shown that cells treated with TKIs tend to acquire genetic
modiﬁcations resulting in resistance to these agents. Better
understanding of the mechanism of action of a drug may also
help in deﬁning potential mechanisms of resistance. Clearly, the
lessons learnt from the targeted agents can aid the design and
evaluation of next generation compounds17.4. Mechanisms of resistance to TKIs
4.1. Mutations
Up to now, more than 100 mutations have been described
affecting more than 70 amino acids causing resistance by
heterogeneous molecular mechanisms18. The most common
and prevalent mechanism leading to against TKIs therapy is
point mutations within the kinase domain, which decrease the
afﬁnity of the TKIs to binding domain. Some mutations may
occur around the binding site, which make extensive conforma-
tional changes, thereby impeding TKIs approach through steric
hindrance. Moreover, some mutations may render the predo-
minance of ATP to competitive binding to the kinase compare
with the second generation TKIs, such as Dasatinib, Nilotinib
or Bosutinib19.
4.1.1. T790M mutations induced by Geﬁtinib
The strongest evidences come from Geﬁtinib, which mimics
adenosine triphosphate (ATP) and is found to bind with high
afﬁnity to EGFR kinase in a competitive manner20. About
70–80% of non-small cell lung cancers harbor a somatic
mutation in the tyrosine kinase domain of the EGFR gene
that responds to Geﬁtinib. EGFR mutation usually occurs in
the ﬁrst 4 exons of the tyrosine kinase domain, and a deletion
involving 5 amino acids (codons 746–750) together with a
point mutation at codon 858 (L858R: replaces leucine 858
with arginine) account for 90% of all EGFR mutations20,21.
This somatic mutation, which seems to arise more frequently
in women and in Asians, is correlated with dramatic clinical
responses to treatment with Geﬁtinib22. It competitively
inhibits the binding of ATP to the EGFR kinase, resulting
in inhibition of phosphorylation, disrupting downstream
signaling and inducing cell apoptosis. Strikingly, direct bind-
ing measurements show that Geﬁtinib binds 20-fold more
tightly to the L858R mutant than to the wild-type enzyme and
produce an initially dramatic response in lung cancer patients
harboring the L858R mutant20,23.
However, patients with EGFR-mutant lung adenocarci-
noma develop acquired resistance to Geﬁtinib after a median
of 10–16 months. More than 60% of these cases harbor a
second EGFR mutation, T790M (threonine-to-methionine
mutation at codon 790 in EGFR), who have the Geﬁtinib
refractory, additionally; other secondary resistance mutations(D761Y, L747S, T854A) seem to be rare24–28. The T790 in
EGFR is located at a key position in the ATP binding cleft,
often referred to as the ‘‘gatekeeper residue.’’ And the
molecular mechanism of TKI-resistance is that the ATP
afﬁnity of the oncogenic L858R mutant is increased by more
than an order of magnitude, leading to resistance to Geﬁtinib.
In a human bronchial epithelial cell line, overexpression of
EGFR T790M confers a growth advantage over cells expres-
sing wild type EGFR29. The development of acquired resis-
tance by the T790M substitution may be modeled in two ways.
In one model, the T790M substitution is absent in the initial
tumor cell population and rises de novo in one or more clonal
populations upon treatment with an EGFR TKI. In the
second model, the T790M substitution pre-exists in cis with
a primary activating mutation in a small population and is
subjected to positive selection pressure in the presence of an
EGFR TKI30.
The T790M mutation also possesses enhanced phosphor-
ylating activity, especially in combination with the L858R
mutation, leading lung cancer cell to survival which indicates
that the T790M mutant is actually an oncogene20. Regales
et al.29 developed mice with inducible expression in type II
pneumocytes of EGFR T790M alone or together with a drug-
sensitive L858R mutation. Both transgenic lines develop lung
adenocarcinomas that require mutant EGFR for tumor
maintenance but are resistant to an EGFR kinase inhibitor.
Notably, EGFR T790M-expressing animals develop tumors
with longer latency than EGFR L858RþT790M-bearing mice
and in the absence of additional kinase domain mutations29.
Interestingly, EGFR T790M alleles have been detected at
lower frequency in untreated NSCLCs, suggesting that they
may confer oncogenic activity to EGFR in addition to their
role in acquired drug resistance31. Additionally, germ line
T790M mutation has been detected in a family that exhibits
inherited predisposition to lung adenocarcinoma32. These
properties may explain that it is initial presence before drug
selection and its rapid selection as the single drug resistance
mutation during therapy with Geﬁtinib22. So a deeper under-
standing of the molecular and cellular basis of this phenom-
enon is crucial to the future development of alternative
therapies to overcome this resistance33.4.1.2. T315I mutation induced by Imatinib
Point mutation within the BCR–ABL kinase domain is another
major cause of acquired resistance. Licensed tyrosine kinase
inhibitors are ineffective against these mutations and their
development reduces life expectancy of CML in chronic phase
from 10 years to just 22 months34. Around 30% of patients with
CML will have to stop Imatinib therapy due to intolerance and
resistance35,36. The in vitro data suggest that Imatinib treatment
confers the mutant cell clone with increased oncogenic ﬁtness.
T315I mutation (resulting in substitution of Ile for a Thr
residue at the ‘‘gatekeeper’’ position 315) is at a higher
frequency than other amino-acid substitutions and is respon-
sible for 14% of reported cases occur at certain sites37.
Furthermore, T315I mutation raises particular concern,
because it also provides resistance to second-generation kinase
inhibitors already approved for clinical use (Nilotinib and
Dasatinib; see Tables 1 and 2)36. Threonine at position 315
forms a crucial hydrogen bond with Imatinib and the absence
of an oxygen atom in the substituted isoleucine prevented
Table 2 In vitro sensitivity of non-mutant and mutant
BCR–ABL against TKIs.
Name Imatinib
(nmol/L)
Nilotinib
(nmol/L)
Dasatinib
(nmol/L)
Native BCR–ABL 260 13 0.8
M244V 2000 38 1.3
G250E 1350 48 1.8
Q252H 1325 70 3.4
Y253F 3475 125 1.4
Y253H 46400 450 1.3
E255K 5200 200 5.6
E255V 46400 430 11
V299L 540 N/A 18
F311L 480 23 1.3
T315A 971 61 125
T315I 46400 42000 4200
F317L 1050 50 7.4
F317V 350 N/A 53
M351T 880 15 1.1
E355G 2300 N/A 1.8
F359V 1825 175 2.2
V379I 1630 51 0.8
L387M 1000 49 2
H396P 350 41 0.6
H396R 1750 41 1.3
Quoted from La Rose´e et al.36.
Note: Imatinib-sensitive, r1000 (nmol/L) (italic); intermediate-
sensitive r3000 (nmol/L) (bold); insensitive 43000 (nmol/L)
(bold italic). Nilotinib-sensitive r50 (nmol/L); intermediate
sensitive r500 (nmol/L); insensitive 4500 (nmol/L). Dasatinib-
sensitive r3 (nmol/L); intermediate sensitive r60 (nmol/L);
insensitive 460 (nmol/L).
Abbreviation: N/A, no data available.
Mechanisms of acquired resistance to TKIs 201bond formation37. Additionally, X-ray crystallography has
revealed how single point mutations in the various domains of
the kinase pocket can affect Imatinib binding36. T315I muta-
tion confers resistance by blocking Imatinib access through
steric hindrance and/or removing of critical hydrogen bonds,
which is resistant to all currently approved BCR–ABL kinase
inhibitors. Various other strategies are in use to optimize the
treatment of CML, including dose optimization of Imatinib,
combination therapy, and use of maintenance therapy with
interferon-alpha and vaccines38,39.
4.1.3. Other mutations induced by related TKIs
Therapeutic inhibition of KIT/PDGFRA kinase activity by
Imatinib has emerged as the ﬁrst-line treatment option in
patients with inoperable gastrointestinal stromal tumor (GIST)40.
However, Imatinib response depends on KIT/PDGFRA muta-
tional status. Most primary mutations of KIT and PDGFRA in
GIST are sensitive to Imatinib and resistance occurs in most
cases because of the acquisition (or emergence through secondary
to the selective pressure) of secondary mutations41. Secondary
mutations in KIT exon 14 (kinase domain), exon 17 (activation
loop: D816V/H, D820Y, N822Y/K, Y823D) and in PDGFRA
exon 14 (D842V, ATP binding site: T670I) confer Imatinib and
Sunitinib-resistance occur in GIST42–48. Like Imatinib, Sunitinib
targets the inactivated conformation of KIT, PDGFRA kinases
and binds with high afﬁnity to the ATP binding pocket. Both ofthem could be effectively against the activation of the primary
mutations of KIT and PDGFRA. However, unlike Imatinib,
Sunitinib does not access the deep hydrophobic part of the ATP
binding site, which explains some differences in the inhibitory
properties of Sunitinib, like the potency against secondary
mutations49. After emergence secondary mutations in KIT and
PDGFRA, the kinases show a reduced binding afﬁnity to the
Imatinib or Sunitinib and still retain the activity
Similarly, activating mutations in the FLT3 are one of the
most common molecular abnormalities found in de novo acute
myeloid leukemia (AML) and have a strong negative prog-
nostic impact50. FLT3 mutations occur within two speciﬁc
regions of the FLT3 gene (juxtamembrane (JM) domain and
tyrosine kinase domain)51. The most common type of FLT3
mutations is that of internal tandem duplication (FLT3/ITD)
in the JM domain, which occurs in up to 30% of patients with
AML and in 5% of patients with myelodysplastic syndrome,
whereas point mutations in the TK domain are observed in
approximately 7% of patients with AML52. Both mutations
represent gain-of-function alterations after treated with TKIs,
which render the kinase less accessible to the inhibitors,
leading to the constitutive activation of FLT3 and the potent
proliferation of leukemic cells.
Some of the best-studied FLT3 targeted inhibitors to date
include PKC412, SU5614, Sorafenib and Sunitinib53. Despite
their remarkable efﬁcacy in reducing the leukemic clone in a
subset of patients with AML, remission in patients who have had
single-agent therapy tends to be short and secondary resistance
develops rapidly54. A screening assay (see Table 3) used to study
resistance proﬁles of three FLT3 inhibitors, PKC412, SU5614
and Sorafenib, showed non-overlapping mechanisms of resis-
tance for these inhibitors. In contrast, an overlapping resistance
proﬁles displayed for ABL inhibitors, namely Imatinib, Nilotinib
and Dasatinib, show incredible high resistance to the T315I
gatekeeper mutation (see Table 2)55. As a result, a combination
of FLT3 inhibitors might be beneﬁcial to the patients who
acquired FLT3 resistance mutations56–59.
Further studies reveal that a great majority of somatic
mutations in PIK3Ca (PIK3CA) are missense mutations cluster-
ing in exons 9 and 20 in patients with NSCLC by EGFR-TKIs
treated. These mutant exons encode a part of the helical and
kinase domains, respectively. E545K andM1043I point mutation
are detected in the heterozygous mutation exons. Mutant
PIK3Ca stimulates the PI3K/AKT1 pathway and promotes cell
growth in several cancers. [3H]-thymidine incorporation data
suggests that PIKC3a, but not PIKC3b or PIKC3g plays a role
in the Imatinib-resistance, resulting in constitutive activation and
oncogenicity60,61. In addition, novel rarely mutations are detected
after treated with new developed TKIs. The fusion gene EML4-
ALK (echinoderm microtubule-associated protein-like 4 gene
and the anaplastic lymphoma kinase gene) is recently identiﬁed
as a novel genetic alteration in NSCLC, which has a strong
oncogenic activity both in vitro and in vivo and may be associated
with resistance to Erlotinib treatment62. Furthermore, from a
Geﬁtinib-resistant patient carrying the activating L858R muta-
tion, Costa et al.63 identiﬁed a novel secondary resistant muta-
tion, L747S in cis to the activating mutation, which attenuated
the up-regulation of Bim (Bcl-2 interacting mediator of cell
death) and reduced apoptosis.
Why do patients acquire these mutations during or after
TKIs therapy? Although the mechanisms are not very clear,
one explanation for these phenomena is that speciﬁc TKIs
Table 3 In vitro sensitivity of native FLT3 and mutant
FLT3-ITD or -TKD against TKIs.
Name PKC412
(nmol/L)
SU5614
(nmol/L)
Soraﬁnib
(nmol/L)
Native FLT3 8 100 8
A627T 97 N/A N/A
N676D 235 400 100
N676I 40 400 40
N676K 100 N/A N/A
N676S 25 100 10
F691I 121 42000 41000
F691L 10 300 41000
G697R 4400 N/A N/A
G697S 53 N/A N/A
C825S 17.5 300 9
D835E 10 350 49
D835N N/A 1000 N/A
D835Y 15 500 49
D839G 20 350 10
D839H 10 300 80
S451F 48 N/A N/A
S84IC 8 125 10
Y842C 4 500 10
Y842D 2 300 250
Y842H 4 700 300
Y842N 9 1000 600
Y842S 4 1000 400
M855T 20 325 10
Adapted from von Bubnoff et al.53,54,56–59.
Note: PKC412-sensitive o12.5 (nmol/L) (italic); intermediate-
sensitive o25.0 (nmol/L) (bold); insensitive Z25 (nmol/L)
(bold italic). SU5614, Sorafenib-sensitive o250 (nmol/L);
intermediate sensitive o500 (nmol/L); insensitive Z500
(nmol/L).
Abbreviation: N/A, no data available.
Yi-fan Chen, Li-wu Fu202treatment help tumor to select the preexisting cell population,
which has a selective advantage24. In addition, the advent
inhibitors increase patients’ genetic instability that promotes
the acquisition of new mutations, which either in drug targets
or the domains those active alternative pathways able to
render cell survival64.
4.2. Modiﬁcations of gene copy number and expression level
Gene copy number alteration and protein expression level
change are another two major mechanisms of oncogenic activa-
tion or signaling pathway modiﬁcation. MET ampliﬁcation
represents the strongest evidence that cells treated with TKIs
tend to acquire genetic alterations to tolerate the inhibition. The
MET gene encodes a transmembrane tyrosine kinase receptor
that acts as an HGF receptor and is involved with invasion,
metastasis, and angiogenesis in tumors65. Activation of MET
has been shown to protect cancer cells from DNA damage66.
Clinical evidences have indicated that ampliﬁcation of the MET
oncogene is observed in 20% of resistance cases in NSCLC
patients with Geﬁtinib or Erlotinib treatment67. As a conse-
quence, tumor cells undergo an adaptive process and acquire
MET ampliﬁcation during the selection, but not due to selection
of a preexisting population of cells. Those results in receptoroverexpression and ligand-independent activation featured as
the concept of ‘‘oncogenic addiction’’68. It is likely that cells
gaining MET extra copies have a selective advantage under the
selective pressure of the drug. In Geﬁtinib resistant HCC827
cells, a focal ampliﬁcation is generated in chromosome 7 that
harboring the MET oncogene69. However, FISH analysis shows
that the acquired copies of MET do not located on chromosome
7 (where the MET gene is positioned) but on a marker
chromosome70. This suggests a mechanism of progressive
acquisition of additional MET copies as a consequence of
asymmetric partitioning of the marker chromosome at mitosis71.
Acquired resistance of NSCLC cells to TKIs is mainly mediated
by a switch to EGFR dependency, which indicates a reciprocal
and complementary relationship between T790M mutation and
MET ampliﬁcation72,73. Unfortunately, MET ampliﬁcation
often accompanies with EGFR ampliﬁcation or KRAS ampli-
ﬁcation, which results in MET TKIs therapy failure71,74.
On the other hand, hepatocyte growth factor (HGF) over-
expression may lead to MET ligand-dependent activation. It is
proved that the mechanism of intrinsic resistance to Geﬁtinib in
NSCLC cells with EGFR-activating mutations is not MET-
ampliﬁed75. Notably in some patients without evidence of EGFR
T790M mutation or MET ampliﬁcation, HGF expression is
greater in the resistant specimen, supporting a role for HGF
alone in promoting drug resistance69. It has been proposed that
activation of HGF/MET signaling can lead to Geﬁtinib resis-
tance in EGFR mutant cancers by activating PI3K/AKT signal
pathway through two different adapters: ERBB3 when MET is
activated by genomic ampliﬁcation or GAB1 (Grb2 associated
binder 1) when MET is activated by HGF69,76.
Another well-described mechanism underlying clinical resis-
tance to Imatinib is BCR–ABL gene ampliﬁcation or
increased mRNA levels of that. It is demonstrated that both
are responsible for an increased level of protein, which is able
to restore oncogenic signaling in presence of a given drug
concentration77. Cytogenetic and molecular techniques, i.e.,
expression of BCR–ABL transcripts is quantiﬁed using the
quantitative real-time PCR assay and BCR–ABL gene ampli-
ﬁcation is detected using ﬂuorescence in situ hybridization, are
currently used to monitor CML therapy for both response and
relapse78. It is also possible that overexpression of BCR–ABL
may be an early phenomenon, preceding the emergence of a
dominant clone with a mutant kinase domain79. Of note, the
mechanism underlying genomic ampliﬁcation is likely due to
the genomic instability. Additionally, maintenance of glucose
uptake for cell metabolism can inhibit p53 activation and
promote resistance when BCR–ABL-expressing cells were
treated with Imatinib80.
On the contrary, Virgili et al.81 reported that loss of the
remaining normal ABL1 allele in CML, which resulted from
cryptic interstitial deletion in 9q34 in patients who did not
achieve a complete cytogenetic remission (CCyR) during
treatment, engenders a novel unexpected mechanism of Ima-
tinib resistance. In addition, patients harbor deletion mutation
on exon 19 of EGFR gene or in-frame deletion delE746-A750
follow T790M mutation or epithelial-to-mesenchymal transi-
tion (EMT), which is related with an acquired resistance to
Geﬁtinib or Erlotinib82,83.
The above results showed that these alterations in gene or
protein expression could account for all resistant mechanisms.
This phenomenon suggests the existence of complicated
relationships among acquired resistance-related genes24.
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Cancer cells can survival and replace the lack of signal in target
therapy by activating modiﬁed signaling pathway, leading to the
acquisition of drug resistance. EGFR-TKI, such as Geﬁtinib
and Erlotinib, shows favorable response to EGFR mutant lung
cancer. However, the responders may acquire resistance induced
by HGF, which activates MET that restores downstream
mitogen activated protein kinase (MAPK)/extracellular signal
regulated kinase (ERK)1/2 and phosphoinositide 3-kinase
(PI3K)/Akt signaling84. Mink et al.85 provided evidence that
paracrine factors secreted from the EGFR-TKI-resistant CAFs
(cancer-associated ﬁbroblast population) mitigate the EGFR-
TKI-mediated blockade of pEGFR and pMAPK in co-cultured
tumor cells, regardless of their EGFR mutational status. Addi-
tionally, elevated IGFR-1b phosphorylation can compensate for
the loss of EGFR signaling function. Either increased insulin-like
growth factor II expression induced by Geﬁtinib, or heterodi-
merization of EGFR and IGFR-1b, may trigger IGFR-1b signal
transduction via activation of Akt and MAPK, and the crosstalk
between EGFR and IGFR-1b signaling are likely to contribute
to resistance of CRC cells to this agent86. Interestingly, Dumka
et al.87 raised the possibility that development of novel means
to enhance p38 MAPK activation in BCR/ABL expressing
cells may be an approach to promote antileukemic effects of
Dasatinib and, possibly, reverse T315I mutation-mediated resis-
tance. In the other way, Src kinase inhibition with Dasatinib
seems to be related to a lack of inhibition of STAT3 and MAPK
signaling88. In a similar manner, Suzuki et al.89 reported a new
mechanism of Imatinib resistance mediated by the activation of
RAS/MAPK pathway and EphB4.
Moreover, several possible mechanisms of acquired EGFR-
TKIs resistance, such as the involvement of insulin-like
growth factor1 receptor (IGF1R) signaling, the loss of PTEN,Figure 1 Schematic summary of the main molecular mechanism of a
ABL kinase domain, including T790M or T315I, can decrease or aboli
as MET or BCR–ABL, leading to overproduction of the TK can conf
ligands mediated tumor cells activation without control; (E) Modiﬁc
constitutive Akt activation; (F) Increased efﬂux or decreased inﬂux o
such as MDR1 or hOCT1, can decrease intracellular concentrations.or PI3K-dependent recruitment of Gab1/Shp2 overexpression,
were reported90. PTEN instability-mediated constitutive Akt
activation is involved in acquired resistance to cetuximab and
also induces de novo resistance to Geﬁtinib91. Exposure of
Imatinib-resistant EOL-1R cells, which showed epigenetic
silencing of the phosphatase and PTEN gene, to Imatinib
failed to dephosphorylate AKT, ERK and STAT5, although
PDGFRa was effectively inactivated92. Another example is
that PTEN inactivation speciﬁcally raises EGFR activity by
impairing the ligand-induced ubiquitylation and degradation
of the activated receptor through destabilization of newly
formed ubiquitin ligase Cbl complexes93. However, loss of
PTEN expression has not been found to be associated with
Lapatinib resistance in any cell lines or clinical specimens94.
When chronically exposing HER2-overexpressing cells to
Lapatinib, resistant cells were found more dependent on
estrogen receptor signaling in terms of cell survival than
parent cells95.
Another mechanism of resistance is that PI3K pathway
inhibitors impaired dephosphorylation of RPS6 (the riboso-
mal S6 protein) in Imatinib-resistant cell lines, suggesting that
an oncogene other than BCR–ABL1 might be responsible for
activation of the PI3K/AKT1/mTOR pathway96. In another
signaling pathway, hyper activation of the pharmacologically
targetable PI3K/mTOR/p70S6K1 axis appears to be central to
the occurrence of Lapatinib resistance in breast cancer97. In
HCC, activation of PI3K/Akt signaling pathway mediates
acquired resistance to Sorafenib therapy98,99.4.4. Mechanisms of resistance related to drug inﬂux/efﬂux
Anticancer drug resistance, including TKIs, almost invariably
emerges and poses major obstacles towards curative therapy ofcquired resistance to TKIs. (A) Mutations in the EGFR or BCR–
sh the inhibitory effect of the drug; (B,C) Gene ampliﬁcation, such
er relative resistance to an inhibitor; (D) Overexpression of RTK
ation of signaling pathways, such as PTEN instability-mediated
f TKIs from the cancer cell, mediated by membrane transporters
Yi-fan Chen, Li-wu Fu204various human malignancies100. In tumor cell lines, multidrug
resistance (MDR) is often associated with an ATP-dependent
decrease in cellular drug accumulation, which is attributed to the
overexpression of certain ATP-binding cassette (ABC) transpor-
ter proteins101. Among ABC transporters, overexpression of
P-glycoprotein (MDR1/P-gp/ABCB1) and the breast cancer
resistance protein (BCRP/ABCG2) confer resistance to Imatinib
in CML or Geﬁtinib in NSCLN102,103. In vitro study showed that
chronic Imatinib exposure of Caco-2 cells resulted in a 50%
decrease in intracellular accumulation of Imatinib, probably due
to enhanced ABCG2- and MDR1-mediated efﬂux, as a result of
upregulated expression of these drug pumps104. Further investiga-
tion indicated that not only Imatinib, Geﬁtinib, Tandutinib but
Dasatinib are high-afﬁnity substrates of MDR1 and ABCG2,
This may explain why these proteins mediated an effective
resistance in cancer cells against above compounds105–108. Recent
evidences have established that both Sunitinib and Sorafenib are
recognized and bound by both MDR1 and ABCG2, and can also
be efﬂuxed in a speciﬁc concentration window109. These ﬁnding
illustrate that MDR1 and ABCG2 play roles in oral absorption,
systemic clearance, and cell penetration of certain TKIs in
patients. Collectively, overexpression of ABC transporters pro-
tects tumor cells from TKIs inhibition that the chemo-immune
system seems to recognize targeted TKI drugs as xenobiotics at
the membrane and tissue barriers and, in case of active extrusion,
protects intracellular targets from the action of the TKIs109. And
overexpression of drug transporters may allow the evolution of
genetic alteration cells that confer more potential drug resistance.
Recently, another drug transporters, human organic cation
transporter 1 (hOCT1), has been implicated as possible
mechanism for promoting Imatinib resistance in CML110.
Clinical data suggested that of patients with higher than
median (high) hOCT1 activity, 85% achieved major molecular
response (MMR) by 24 months, versus 45% with no more
than a median (low) hOCT1 activity111. Whereas hOCT1-
mediated inﬂux may be a key determinant of molecular
response to Imatinib, it is unlikely to impact on cellular
uptake and patient response to Nilotinib104,112. In conclusion,
differential expression of inﬂux (hOCT1) and efﬂux (MDR1,
ABCG2) transporters may be a critical determinant of
intracellular drug levels and, hence, resistance to Imatinib113.
In fact, TKIs such as Nilotinib, Lapatinib, Geﬁtinib and
Erlotinib showed an effective outcome of reverse ABC
transporters by blocking their efﬂux function106,114-116.
Noguchi et al.117 found that Erlotinib effectively suppressed
MDR1-mediated resistance to vincristine and paclitaxel, but
did not suppress resistance to mitoxantrone and doxorubicin.
Conversely, Erlotinib appeared to enhance MDR1-mediated
resistance to mitoxantrone in K562/MDR cells. Nevertheless,
a better understanding of the pharmacological interactions of
TKIs used in combinational chemotherapy is important when
coadministration of transporter modulators.5. Conclusions
So far, a lot of TKIs have been identiﬁed and approved for
treatment of cancer. However, the responders acquire resistance
almost without exception. Understanding mechanisms of resis-
tance to TKIs and developing treatment strategies to overcome
resistance are the most important in the current research.
Moreover, clinical monitoring of mutations, certain proteinsoverexpression, or gene ampliﬁcations should allow loss response
to TKIs to be recognized. In addition, quiescence, microenviron-
ment or microRNA may play roles in mediating resistance to
TKIs. Importantly, these results also underscore the notion that
a single cancer can simultaneously develop resistance induced by
several mechanisms (Fig. 1)68. On the other hand, the lessons
learnt from the TKIs resistance can drive researchers to develop
next generation of TKIs and to design highly effective indivi-
dualized therapies for cancer patients.References
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